• Auxilium Pharmaceuticals Inc., of Malvern, Pa., said its supplemental Biologics License Application for Xiaflex (collagenase clostridium histolyticum), a therapy for the potential treatment of Peyronie's disease (PD) has been accepted for filing and granted standard review status by the FDA.